Furthermore, high levels of LA pathway genes, including FDX1, LIAS, LIPT1, and DLD, correlated with prolonged RFS, suggesting that targeting the LA pathway in cuproptosis may be a potential therapeutic strategy in patients with ER+ BC. This evidence concerns the gene ESR1 and breast cancer.